Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GTS 21

Drug Profile

GTS 21

Alternative Names: DMXB-A; DMXB-A sustained release; DMXB-A-SR

Latest Information Update: 15 May 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical; University of Florida
  • Developer CoMentis
  • Class Benzylidene compounds; Neuroprotectants; Nootropics; Pyridines; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder
  • Discontinued Alzheimer's disease; Cognition disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Apr 2015 University of Florida plans a phase II trial for Smoking withdrawal in USA (NCT02432066)
  • 04 Apr 2014 University of Colorado at Denver plans a phase I trial for Autistic disorder in USA (NCT02111551)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top